Most Recent Additions*
Effects Of Semaglutide On Chronic Kidney Disease Outcomes: A Post Hoc Pooled Analysis From The SUSTAIN 6 And PIONEER 6 Trials
Katherine Tuttle, David Cherney, Samy Hadjadj, Thomas Idorn, Ofri Mosenzon, Vlado Perkovic, Soren Rassmussen, Benjamin Wolthers, and Stephen C. Bain
Effects of Semaglutide on CKD Outcomes: A Post Hoc Pooled Analysis from the SUSTAIN 6 and PIONEER 6 Trials
Katherine Tuttle, David Cherney, Samy Hadjadj, Thomas Idorn, Ofri Mosenzon, Vlado Perkovic, Soren Rassmussen, Benjamin Wolthers, and Stephen C. Bain
REDUCTION IN THE RATE OF EGFR DECLINE WITH SEMAGLUTIDE VS PLACEBO: A POST HOC POOLED ANALYSIS OF SUSTAIN 6 AND PIONEER 6
Katherine Tuttle, David Cherney, Samy Hadjadj, Thomas Idorn, Ofri Mosenzon, Vlado Perkovic, Soren Rassmussen, Benjamin Wolthers, and Stephen C. Bain
Using Autoencoders for Imputing Missing Data in eGFR Decline Trajectories of Patients with CKD
Davina J. Zamanzadeh, Panayiotis Petousis, Tyler Austin Davis, Andres Olav Garlid, Xiaoyan Wang, Keith C. Norris, Obidiugwu Duru, Katherine Tuttle, Alex Bui, Susanne B. Nicholas, and CURE-CKD Registry Study Team
The Effect of Caloric Restriction and Aerobic Exercise on Serum FGF-23 in Patients with Moderate to Severe CKD
Elvis A. Akwo, Thomas G. Stewart, Cassianne Robinson-Cohen, Adriana Hung, Jonathan Himmelfarb, Katherine Tuttle, and Talat Alp Ikizler
Feature | Thrombosis and COVID-19: FAQs For Current Practice
Geoffrey D. Barnes, Adam Cuker, Tyler J Gluckman, Gregory Piazza, and Deborah M. Siegal
Outcomes of Acute Myocardial Infarction Hospitalizations During the COVID-19 Pandemic
Margaret Krasne, Tyler J Gluckman, Joseph Edward Marine, Roger S. Blumenthal, and Garima Sharma
CT301 - A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors
Juanita S. Lopez, Ross Camidge, Marco Iafolla, Sylvie Rottey, Martin Schuler, Matthew Hellmann, Ali Balmanoukian, Luc Dirix, Michael Gordon, Ryan Sullivan, Brian S. Henick, Charles Drake, Kit Wong, Patricia LoRusso, Patrick Ott, Lawrence Fong, Aglaia Schiza, Jeffrey Yachnin, Christian Ottensmeier, Fadi Braiteh, Johanna Bendell, Rom Leidner, George Fisher, Guy Jerusalem, Laura Molenaar-Kuijsten, Marcus Schmidt, Scott A. Laurie, Raid Aljumaily, Achim Rittmeyer, Eelke Gort, Ignacio Melero, Lars Mueller, Rachel Sabado, Patrick Twomey, Jack Huang, Manesh Yadav, Jingbin Zhang, Felicitas Mueller, Evelyna Derhovanessian, Ugur Sahin, Ozlem Tureci, and Thomas Powles
Response to anti-PD-1 and anti-LAG-3 immune checkpoint blockade (ICB) is associated with induction of pro-inflammatory Tregs
Elizabeth Sturgill, Courtney Mick, Johanna K. Kaufmann, and William L. Redmond
Safety and tolerability of MEDI0562 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.
Jonathan Wade Goldman, Sarina Anne Piha-Paul, Brendan Curti, Katrina Pedersen, Todd Michael Bauer, Stefanie L. Groenland, Richard D. Carvajal, Vaishali Chhaya, Scott A. Hammond, Katie Streicher, Danielle Michelle Townsley, Young Kwang Chae, Jens Voortman, Aurelien Marabelle, and John D. Powderly
Sgnlva-005: Open-label, phase II study of ladiratuzumab vedotin (LV) for advanced aerodigestive tract malignancies.
Ian Churchill Anderson, Yinghui Wang, Zejing Wang, and Rachel E Sanborn
PD47-04 SINGLE CELL RNA-SEQUENCING OF FRESH SUPERFICIAL NON-MUSCLE INVASIVE BLADDER CANCER DEMONSTRATES GENE EXPRESSSION PATHWAY DIFFFERENCES BETWEEN HIGH AND LOW GRADE TUMORS
Stanley Malkowiicz, Brian D. Piening, Alexa Dowdell, David Walls, Nik Nair, Baoli Chang, and Brendan Keating
Abstract B01: Surgical outcomes following neoadjuvant hypofractionated radiation in combination with nivolumab: High rate of pathologic complete response in patients with p16+ head and neck squamous cell carcinoma
Richard Bryan Bell, Rom Leidner, Marcus Couey, Ashish Patel, Amber L Watters, Hong Ziao, Carlo Bifulco, Brian D. Piening, George Morris, Lessli Rushforth, Dawn Brucker, Shorin Nemeth, Kristina H Young, Michael J. Gough, and Marka R Crittenden
Halting the Cascade of Chronic Kidney Disease: Can We Catch Patients Before They Fall?
David C. Wheeler, David Cherney, and Katherine Tuttle
Cohort Expansion Study of Neoadjvuant Immunoradiotherapy in Locoregionally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma
Richard Bryan Bell, Rom Leidner, Kristina H Young, Brendan Curti, Marcus Couey, Ashish Patel, Amber L Watters, Hong D Xiao, George Morris, Lessli Rushforth, Michael J. Gough, and Marka R Crittenden
Dendritic Cell Maturation Defines Immunological Responsiveness of Tumors and Radiation
Tiffany C. Blair, Shelly Bambina, Alejandro F Alice, Gwen Kramer, Terry R Medler, Jason R Baird, Miranda L. Broz, Garth Tormoen, Victoria Troesch, Marka R Crittenden, and Michael J. Gough
The Green Print: Advancement of Environmental Sustainability in Healthcare
Jodi D. Sherman, Cassandra Thiel, Andrea MacNeill, Matthew J. Eckelman, Robert Dubrow, Harriet Hopf, Robert Lagasse, Joseph Bialowitz, Anthony Costello, McGain Forbes, Rachel Stancliffe, Paul Anastas, Laura Anderko, Mark Baratz, Stefi Barna, Urvashi Bhatnagar, Jason Burnham, Yizhen Cai, Andy Cassels-Brown, Alexander FP Cimprich, Heidi Cole, Lorea Coronado-Garcia, Brett Duane, Gabriella Grisotti, Arthy Hartwell, Varshini Kumar, Ann Kurth, Michael Leapman, Daniel S. Morris, Michael Overcash, Abhijeet G. Parvatker, David Pencheon, Adam Pollard, Bernard Robaire, Karl Rockne, Blair L. Sadler, Elizabeth Schenk, Tushar Sethi, L Scott Sussman, Jeff Thompson, Janet M. Twomey, Sten H. Vermund, Daneil Vukelich, Natasha Wasim, Debbie Wilson, Steven B. Young, Julie Zimmerman, and Melissa M. Bilec
A phase I/II study of HB-201, an arenavirus-based cancer immunotherapy, alone, or in combination with anti-PD-1 in patients with HPV16+ cancers.
Bharat Burman, Jiaxin Niu, Rom Leidner, Ding Wang, Debra L. Richardson, Corinne Iacobucci, Andy Hwang, Xiaoping Qing, Igor Matushansky, Dmitriy Zamarin, Alan Loh Ho, David G. Pfister, and Marshall R. Posner
A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing, advanced solid tumors.
Aaron Scott Mansfield, David S. Hong, Christine L. Hann, Anna F. Farago, Himisha Beltran, Saiama Naheed Waqar, Andrew Eugene Hendifar, Lowell Brian Anthony, Matthew H Taylor, Alan Haruo Bryce, Scott T. Tagawa, Karl D. Lewis, Jiaxin Niu, Christine H. Chung, James M. Cleary, Michael Rossi, Carrianne Ludwig, Ricardo Valenzuela, Yan Luo, and Rahul Raj Aggarwal
*Updated as of 11/29/20.
